Tuesday - May 19, 2026
GSK's RSV Vaccine, Arexvy, Receives Expanded Approval in Japan for Adults Aged 18-59 at Increased Risk
May 19, 2026
LONDON, England, May 19 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on May 18, 2026:

* * *

GSK's RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18-59 at increased risk

* First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan

* In Japan, millions of adults live with certain chronic conditions that . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products